83 related articles for article (PubMed ID: 7558105)
1. Cytogenetic and viral studies in nasopharyngeal carcinomas in patients of Indian origin.
Kumari P; Augustus M; Naik U; Ravi V; Shenoy AM; Rao CR; Kumar RV
Indian J Cancer; 1995 Mar; 32(1):10-4. PubMed ID: 7558105
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus in nasopharyngeal carcinoma in Indian patients.
Rathaur RG; Chitale AR; Banerjee K
Indian J Cancer; 1999; 36(2-4):80-90. PubMed ID: 10921211
[TBL] [Abstract][Full Text] [Related]
3. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.
Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX
Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
Liu MT; Yeh CY
Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
[TBL] [Abstract][Full Text] [Related]
5. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of multiple antibodies to Epstein-Barr virus as markers for detecting patients with nasopharyngeal carcinoma.
Liu MY; Chang YL; Ma J; Yang HL; Hsu MM; Chen CJ; Chen JY; Yang CS
J Med Virol; 1997 Jul; 52(3):262-9. PubMed ID: 9210034
[TBL] [Abstract][Full Text] [Related]
7. Expression of Epstein-Barr virus-encoded RNAs as a marker for metastatic undifferentiated nasopharyngeal carcinoma.
Chao TY; Chow KC; Chang JY; Wang CC; Tsao TY; Harn HJ; Chi KH
Cancer; 1996 Jul; 78(1):24-9. PubMed ID: 8646721
[TBL] [Abstract][Full Text] [Related]
8. Demonstration of Epstein-Barr virus antibodies in serum of patients with nasopharyngeal carcinoma.
Kumar S; Wairagkar NS; Mahanta J
Indian J Cancer; 2001; 38(2-4):72-5. PubMed ID: 12593442
[TBL] [Abstract][Full Text] [Related]
9. The mechanism of Epstein-Barr virus infection in nasopharyngeal carcinoma cells.
Lin CT; Lin CR; Tan GK; Chen W; Dee AN; Chan WY
Am J Pathol; 1997 May; 150(5):1745-56. PubMed ID: 9137098
[TBL] [Abstract][Full Text] [Related]
10. ELISA for the detection of serum and saliva IgA against the BMRFI gene product of Epstein-Barr virus.
Nadala EC; Tan TM; Wong HM; Ting RC
J Med Virol; 1996 Sep; 50(1):93-6. PubMed ID: 8890046
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma.
Niedobitek G; Agathanggelou A; Nicholls JM
Semin Cancer Biol; 1996 Aug; 7(4):165-74. PubMed ID: 8946600
[TBL] [Abstract][Full Text] [Related]
12. [Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx].
Mazeron MC
Bull Cancer Radiother; 1996; 83(1):3-7. PubMed ID: 8679277
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus infection in precursor lesions of nasopharyngeal carcinoma.
Zhong BL; Zong YS; Lin SX; Zhang M; Liang YJ
Ai Zheng; 2006 Feb; 25(2):136-42. PubMed ID: 16480574
[TBL] [Abstract][Full Text] [Related]
14. New BZLF1 sequence variations in EBV-associated undifferentiated nasopharyngeal carcinoma in southern China.
Ji KM; Li CL; Meng G; Han AD; Wu XL
Arch Virol; 2008; 153(10):1949-53. PubMed ID: 18807115
[TBL] [Abstract][Full Text] [Related]
15. Detection of transcripts initiated from two viral promoters (Cp and Wp) in Epstein-Barr virus-infected nasopharyngeal carcinoma cells and biopsies.
Chang Y; Sheen TS; Lu J; Huang YT; Chen JY; Yang CS; Tsai CH
Lab Invest; 1998 Jun; 78(6):715-26. PubMed ID: 9645762
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus immune response in high-risk nasopharyngeal carcinoma families in Greenland.
Friborg J; Jarrett RF; Liu MY; Falk KI; Koch A; Olsen OR; Duncan P; Wohlfarht J; Chen JY; Melbye M
J Med Virol; 2007 Dec; 79(12):1877-81. PubMed ID: 17935169
[TBL] [Abstract][Full Text] [Related]
18. The association of squamous cell carcinomas of the nasopharynx with Epstein-Barr virus shows geographical variation reminiscent of Burkitt's lymphoma.
Nicholls JM; Agathanggelou A; Fung K; Zeng X; Niedobitek G
J Pathol; 1997 Oct; 183(2):164-8. PubMed ID: 9390028
[TBL] [Abstract][Full Text] [Related]
19. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
Leung SF; Chan AT; Zee B; Ma B; Chan LY; Johnson PJ; Lo YM
Cancer; 2003 Jul; 98(2):288-91. PubMed ID: 12872347
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma.
Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM
J Clin Virol; 2008 Aug; 42(4):343-52. PubMed ID: 18455473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
